New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Lecanemab is a monoclonal antibody with high affinity to amyloid-beta soluble protofibrils. It was approved in 2023 as an IV ...

Eisai is continuing to advance care in Alzheimer’s disease via this multi-dimensional, yet targeted path to our ultimate goal: prevention and stopping progression.

Review quarterly and annual revenue, net income, and cash flow for Eisai Co Ltd (4523:XTKS) stock through the last fiscal year.

Japanese drugmaker Eisai said Tuesday that Ivan Cheung, chairman of its U.S. operations and global head of its Alzheimer’s disease unit, will retire at the end of the month.

Get the latest Eisai Co., Ltd. (ESAIY) stock news and headlines to help you in your trading and investing decisions.

CHICAGO, Sept 30 (Reuters) - Clear evidence this week that Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab drug lecanemab slows cognitive decline in early stage dementia has ...

Japanese drugmaker Eisai said on Tuesday it was targeting revenue of 10 billion yen ($66.5 million) from its recently approved Alzheimer's drug, Leqembi, by March 2024.

Eisai Co. said a volunteer died while using the company’s experimental Alzheimer’s drug lecanemab in a clinical trial, but that it wasn’t clear if the death was directly caused by the drug.